492 related articles for article (PubMed ID: 11334404)
1. Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death.
Finegood DT; McArthur MD; Kojwang D; Thomas MJ; Topp BG; Leonard T; Buckingham RE
Diabetes; 2001 May; 50(5):1021-9. PubMed ID: 11334404
[TBL] [Abstract][Full Text] [Related]
2. Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat.
Smith SA; Lister CA; Toseland CD; Buckingham RE
Diabetes Obes Metab; 2000 Dec; 2(6):363-72. PubMed ID: 11225966
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of orexin gene expression by severe obesity in the rats: studies in Zucker fatty and zucker diabetic fatty rats and effects of rosiglitazone.
Cai XJ; Lister CA; Buckingham RE; Pickavance L; Wilding J; Arch JR; Wilson S; Williams G
Brain Res Mol Brain Res; 2000 Apr; 77(1):131-7. PubMed ID: 10814839
[TBL] [Abstract][Full Text] [Related]
4. Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555.
Upton R; Widdowson PS; Ishii S; Tanaka H; Williams G
Br J Pharmacol; 1998 Dec; 125(8):1708-14. PubMed ID: 9886762
[TBL] [Abstract][Full Text] [Related]
5. Improvement of glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl peptidase inhibitor P32/98: comparison with and combination with rosiglitazone.
Wargent E; Stocker C; Augstein P; Heinke P; Meyer A; Hoffmann T; Subramanian A; Sennitt MV; Demuth HU; Arch JR; Cawthorne MA
Diabetes Obes Metab; 2005 Mar; 7(2):170-81. PubMed ID: 15715890
[TBL] [Abstract][Full Text] [Related]
6. A nonspecific phosphotyrosine phosphatase inhibitor, bis(maltolato)oxovanadium(IV), improves glucose tolerance and prevents diabetes in Zucker diabetic fatty rats.
Winter CL; Lange JS; Davis MG; Gerwe GS; Downs TR; Peters KG; Kasibhatla B
Exp Biol Med (Maywood); 2005 Mar; 230(3):207-16. PubMed ID: 15734724
[TBL] [Abstract][Full Text] [Related]
7. Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes.
Shimabukuro M; Zhou YT; Levi M; Unger RH
Proc Natl Acad Sci U S A; 1998 Mar; 95(5):2498-502. PubMed ID: 9482914
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution.
Pickavance LC; Tadayyon M; Widdowson PS; Buckingham RE; Wilding JP
Br J Pharmacol; 1999 Dec; 128(7):1570-6. PubMed ID: 10602338
[TBL] [Abstract][Full Text] [Related]
9. Modulation of adipoinsular axis in prediabetic zucker diabetic fatty rats by diazoxide.
Alemzadeh R; Tushaus KM
Endocrinology; 2004 Dec; 145(12):5476-84. PubMed ID: 15319354
[TBL] [Abstract][Full Text] [Related]
10. Phlorizin treatment prevents the decrease in plasma insulin levels but not the progressive histopathological changes in the pancreatic islets during aging of Zucker diabetic fatty rats.
Janssen SW; Martens GJ; Sweep CG; Span PN; Verhofstad AA; Hermus AR
J Endocrinol Invest; 2003 Jun; 26(6):508-15. PubMed ID: 12952363
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats.
Buckingham RE; Al-Barazanji KA; Toseland CD; Slaughter M; Connor SC; West A; Bond B; Turner NC; Clapham JC
Diabetes; 1998 Aug; 47(8):1326-34. PubMed ID: 9703335
[TBL] [Abstract][Full Text] [Related]
12. Variation in characteristics of islets of Langerhans in insulin-resistant, diabetic and non-diabetic-rat strains.
Jones HB; Nugent D; Jenkins R
Int J Exp Pathol; 2010 Jun; 91(3):288-301. PubMed ID: 20384904
[TBL] [Abstract][Full Text] [Related]
13. Insulin secretory defect in Zucker fa/fa rats is improved by ameliorating insulin resistance.
de Souza CJ; Yu JH; Robinson DD; Ulrich RG; Meglasson MD
Diabetes; 1995 Aug; 44(8):984-91. PubMed ID: 7622005
[TBL] [Abstract][Full Text] [Related]
14. Troglitazone prevents and reverses dyslipidemia, insulin secretory defects, and histologic abnormalities in a rat model of naturally occurring obese diabetes.
Jia DM; Tabaru A; Nakamura H; Fukumitsu KI; Akiyama T; Otsuki M
Metabolism; 2000 Sep; 49(9):1167-75. PubMed ID: 11016899
[TBL] [Abstract][Full Text] [Related]
15. Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability.
Oakes ND; Thalén PG; Jacinto SM; Ljung B
Diabetes; 2001 May; 50(5):1158-65. PubMed ID: 11334421
[TBL] [Abstract][Full Text] [Related]
16. Effect of chronic rosiglitazone, metformin and glyburide treatment on beta-cell mass, function and insulin sensitivity in mZDF rats.
Atkinson LL; McDonald-Dyck C; Benkoczi C; Finegood DT
Diabetes Obes Metab; 2008 Sep; 10(9):780-90. PubMed ID: 17970758
[TBL] [Abstract][Full Text] [Related]
17. Defective fatty acid-mediated beta-cell compensation in Zucker diabetic fatty rats. Pathogenic implications for obesity-dependent diabetes.
Hirose H; Lee YH; Inman LR; Nagasawa Y; Johnson JH; Unger RH
J Biol Chem; 1996 Mar; 271(10):5633-7. PubMed ID: 8621426
[TBL] [Abstract][Full Text] [Related]
18. Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats.
Higa M; Zhou YT; Ravazzola M; Baetens D; Orci L; Unger RH
Proc Natl Acad Sci U S A; 1999 Sep; 96(20):11513-8. PubMed ID: 10500208
[TBL] [Abstract][Full Text] [Related]
19. Retinoid X receptor agonists have anti-obesity effects and improve insulin sensitivity in Zucker fa/fa rats.
Liu YL; Sennitt MV; Hislop DC; Crombie DL; Heyman RA; Cawthorne MA
Int J Obes Relat Metab Disord; 2000 Aug; 24(8):997-1004. PubMed ID: 10951538
[TBL] [Abstract][Full Text] [Related]
20. Rosiglitazone protects against ischemia/reperfusion-induced leukocyte adhesion in the zucker diabetic fatty rat.
Johns DG; Ao Z; Eybye M; Olzinski A; Costell M; Gruver S; Smith SA; Douglas SA; Macphee CH
J Pharmacol Exp Ther; 2005 Dec; 315(3):1020-7. PubMed ID: 16123307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
